<DOC>
	<DOCNO>NCT01716416</DOCNO>
	<brief_summary>This phase I trial study side effect best dose pazopanib hydrochloride ( pazopanib ) give together cetuximab treat patient incurable recurrent metastatic head neck cancer . Pazopanib may stop growth cancer block blood flow tumor . Pazopanib may also block enzyme need cell growth . Cetuximab monoclonal antibody block ability tumor cell grow spread . Giving pazopanib cetuximab may provide effective treatment patient advanced head neck cancer .</brief_summary>
	<brief_title>Pazopanib Plus Cetuximab Incurable Head Neck Squamous Cell Carcinoma ( HNSCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patient must histologically confirm diagnosis incurable metastatic recurrent head neck squamous cell carcinoma Patient must measurable disease defined lesion accurately measure least one dimension ( long diameter record ) ≥10 mm CT scan , ≥20 mm chest xray , ≥10 mm caliper clinical exam ( Expanded Cohort ; patient without measurable disease RECIST 1.1 criterion evaluable disease eligible dosefinding phase ) . Patient must ≥ 18 year age . Patient must ECOG performance status 01 Patient must normal bone marrow organ function define : Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Hemoglobin ≥ 9.0 g/dL INR ≤ 1.2 x IULN ; patient receive anticoagulant therapy eligible INR stable within recommended range desire level anticoagulation aPTT ≤ 1.2 x IULN Corrected QT interval ( QTc ) &lt; 480 msec Total bilirubin ≤ 1.5 x IULN AST ( SGOT ) ≤ 2.5 x IULN ALT ( SGPT ) ≤ 2.5 x IULN Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 50 mL/min/1.73 m2 patient creatinine level &gt; 1.5 mg/dL Urine protein creatinine ratio ( UPC ) &lt; 1 ; UPC ≥ 1 , 24hour urine protein must assess ; patient must 24hour urine protein value &lt; 1 g eligible Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) begin 14 day prior first dose pazopanib , dose period , least 28 day last dose pazopanib . Patient must able understand willing sign IRB approve write informed consent document . For expanded cohort , patient must prior therapy EGFRspecific monoclonal antibody EGFRspecific TKI treatment incurable HNSCC . Prior therapy EGFRspecific monoclonal antibody part definitive treatment curable HNSCC acceptable occur 3 month prior study enrollment . For dosefinding cohort , prior EGFRspecific therapy incurable setting allow . Patient must radiation therapy , minor surgery , tumor embolization 14 day prior first dose pazopanib . Patient must chemotherapy , immunotherapy , biologic therapy , hormonal therapy , investigational therapy within 14 day 5 halflives drug prior first dose pazopanib . For patient enrol phase I portion study , requirement apply prior treatment cetuximab . Patient must prior major surgery , trauma , presence nonhealing wound , fracture , ulcer within 28 day prior first dose study drug . Patient must history malignancy ≤ 2 year previous exception completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma . Patient must receive medication strong CYP3A4 inhibitor begin 14 day prior first dose study drug . Strong CYP3A4 inhibitor include ( limited ) : antibiotic clarithromycin , telithromycin , troleandromycin ; protease inhibitor ritonavir , indinavir , saquinavir , nelfinavir , lopinavir ; antifungal itraconazole , ketoconazole , voriconazole ; antidepressant nefazodone . Patient must receive investigational agent . Patient must experience ongoing toxicity prior anticancer therapy &gt; grade 1 progress severity , except alopecia . Patient must history clinical evidence central nervous system metastasis leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose pazopanib . Patient must history allergic reaction attribute compound similar chemical biologic composition pazopanib , cetuximab , agent use study . Patient must clinically significant gastrointestinal abnormality may increase risk GI bleed include , limited , active peptic ulcer disease , know intraluminal metastatic lesion risk bleeding , inflammatory bowel disease ( e.g. , ulcerative colitis , Crohn 's disease ) , GI condition increase risk perforation , history abdominal fistula GI perforation intraabdominal abscess within 28 day prior begin study treatment . Patient must clinically significant abnormality may affect absorption investigational product include , limited , malabsorption syndrome major resection stomach small bowel . Patient must uncontrolled intercurrent illness within 6 month prior study entry include , limited , ongoing active infection , Class III IV congestive heart failure ( defined New York Heart Association ( NYHA ) ) , unstable angina pectoris , cardiac arrhythmia , myocardial infarction , cardiac angioplasty stenting , coronary artery bypass graft surgery , symptomatic peripheral vascular disease , psychiatric illness/social situation would limit compliance study requirement . Patient must poorly control hypertension ( define systolic blood pressure ≥ 140 mmHg diastolic blood pressure ≥ 90 mmHg ) . Initiation adjustment antihypertensive medication permit prior study entry . Blood pressure must reassess two occasion separate minimum one hour ; occasion , mean ( 3 reading ) assessment must &lt; 140/90 mmHg patient eligible study . Patient must history cerebrovascular accident include transient ischemic attack within past 6 month . Patients recent deep venous thrombosis pulmonary embolism treat therapeutic anticoagulating agent least 6 week eligible long INR stable . Patient must evidence active bleeding bleed diathesis . Patient must know endobronchial lesion and/or lesion infiltrate major pulmonary vessel . Patient must experience hemoptysis excess 2.5 mL within 8 week prior first dose pazopanib . Patient must pregnant and/or breastfeed . Patient must negative serum pregnancy test within 14 day study entry . Patient must know HIVpositive combination antiretroviral potential pharmacokinetic interaction pazopanib . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>